
NASDAQHealthcareBiotechnology
Latest quote
$1.52
−$0.135 · -8.16%
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
Previous close
$1.52
−$0.135 · -8.16%
Regular session · ET · Market data may be delayed.
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
Day range
Current $1.52
52-week range
Current $1.52
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
61
Undervalued
Sentiment
56
Mixed
Risk
52
Elevated Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
Day range
Current $1.52
52-week range
Current $1.52
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (AUD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | 5.44M AUD | 4.02M AUD | 3.92M AUD | 5.12M AUD |
| Cost of goods sold | 113.01K AUD | 127.52K AUD | 214.3K AUD | 285.07K AUD | 364.67K AUD |
| Gross profit | −113.01K AUD | 5.31M AUD | 3.8M AUD | 3.63M AUD | 4.76M AUD |
| Research and development | 17.24M AUD | 14.4M AUD | 18.64M AUD | 13.2M AUD | 14.75M AUD |
| Selling, general, and administrative | 10.44M AUD | 5.48M AUD | 4.76M AUD | 5.04M AUD | 5.51M AUD |
| Operating expenses | 27.69M AUD | 19.89M AUD | 23.41M AUD | 18.24M AUD | 20.26M AUD |
| Interest income | 1.68M AUD | 446.29K AUD | 268.42K AUD | 16.44K AUD | 2.5K AUD |
| Depreciation and amortization | 113.01K AUD | 139.72K AUD | 147.53K AUD | 102.26K AUD | 54.21K AUD |
| Operating income | −27.8M AUD | −14.57M AUD | −19.6M AUD | −14.64M AUD | −15.5M AUD |
| Net income | −22.89M AUD | −12.15M AUD | −19.12M AUD | −13.81M AUD | −12.85M AUD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$8.00
426.32% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 9, 2023 | 1:10 | — | — |
Stock split | Mar 24, 2016 | 1:6 | — | — |
Effective Jan 9, 2023
1:10
Effective Mar 24, 2016
1:6
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.